Table 2.
Discovery (n=154) | Validation (n=151) | Total (n=305) | ||
---|---|---|---|---|
Sex, F/M (% male) | 48/106 (45.3%) | 54/97(55.7%) | 102/203 (50.2%) | |
| ||||
Age (yrs) | Mean ± SD | 62.80 ± 9.57 | 62.86 ± 9.05 | 62.83 ± 9.3 |
Range | 36 – 79 | 35 – 80 | 35 – 80 | |
| ||||
Disease Duration (yrs) | Mean ± SD | 3.82 ± 1.58 | 3.83 ± 1.42 | 3.82± 1.5 |
Range | 1 – 8 | 1 – 9 | 1 – 9 | |
| ||||
MMSE | Mean ± SD | 28.72 ± 2.30 | 28.85 ± 2.10 | 28.79 ± 2.20 |
Range | 8 – 30 | 9 – 30 | 8 – 30 | |
| ||||
UPDRS total | Mean ± SD | 45.12 ± 13.37 | 43.84 ± 14.72 | 44.49 ± 14.05 |
Range | 10 – 83 | 8.5 – 88 | 8.5 – 88 | |
| ||||
UPDRS motor | Mean ± SD | 30.22 ± 10.30 | 29.61 ± 10.91 | 29.92 ± 10.59 |
Range | 6 – 59 | 4.5 – 62 | 4.5– 62 | |
| ||||
Hoehn and Yahr | Median | 2 | 2 | 2 |
Range | 1 – 3 | 1 – 4 | 1 – 4 | |
| ||||
CSF Aβ42 (pg/mL) | Mean ± SD | 233.37 ± 80.06 | 231.01 ± 72.14 | 232.21 ± 76.14 |
Range | 12.13 – 631.25 | 15.53 – 464.04 | 12.13 – 631.25 | |
| ||||
CSF t-tau (pg/mL) | Mean ± SD | 47.67 ± 25.18 | 46.65 ± 24.94 | 47.16 ± 25.02 |
Range | 13.38 – 171.80 | 12.29 – 191.42 | 12.29 – 191.42 | |
| ||||
CSF p-tau (pg/mL) | Mean ± SD | 22.95 ± 11.11 | 24.22 ± 13.06 | 23.58 ± 12.11 |
Range | 3.85 – 62.90 | 4.35 – 96.93 | 3.85 – 96.93 | |
| ||||
CSF p-tau/t-tau | Mean ± SD | 0.52 ± 0.21 | 0.56 ± 0.24 | 0.54 ± 0.23 |
Range | 0.16 – 1.09 | 0.16 – 1.83 | 0.16 – 1.83 | |
| ||||
CSF t-tau/Aβ42 | Mean ± SD | 0.24 ± 0.33 | 0.22 ± 0.13 | 0.23 ± 0.26 |
Range | 0.10 – 4.14 | 0.10 – 0.81 | 0.10 – 4.14 | |
| ||||
CSF p-tau/Aβ42 | Mean ± SD | 0.12 ± 0.20 | 0.12 ± 0.13 | 0.12 ± 0.17 |
Range | 0.03 – 2.45 | 0.03 – 1.45 | 0.03 – 2.45 |
MMSE:Pre-washout Mini Mental State Examination prior to the beginning of Phase 2; UPDRS: Unified Parkinson Disease Rating Scale; CSF: cerebrospinal fluid; Aβ42: amyloid beta peptide 1-42; p-tau: phosphorylated tau; t-tau: total tau.